Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Combined Synopsis/Solicitation opportunity from Department Of Health And Human Services was posted on December 23, 2024. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

BENCHTOP BIOCONTAINMENT ENCLOSURE

Closed
NOI-NIAID-25-2252185Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

General Info

Contract Value

$29,800

NAICS

339999 - All Other Miscellaneous Manufacturing

Place of Performance

MD, 20892, USA

Set-Aside

NONE

Award Issued Date

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

Combined Synopsis

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
Contacts2 people available
OfficeBETHESDA, MD, 20892, USA

Full Description

Show more
POSTING NOTICE NOI-NIAID-25-2252185 This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with bioBubble 1411 E Magnolia St Fort Collins, CO 80524 The Viral Persistence and Dynamics Section of the NIH/Vaccine Research Center is a biological science lab. Single-cell studies are critical for understanding the dynamics of HIV infection, latency, and reactivation within cellular populations. The microfluidics platform allows for precise manipulation and observation of individual cells but requires containment to meet biosafety standards for working with HIV. The benchtop biocontainment enclosure provides the necessary physical barrier to ensure compliance with biosafety level BSL2 requirements. It will safeguard personnel, the laboratory environment, and sensitive equipment from potential exposure to infectious materials. VRC seeks to procure (1) one Benchtop Biocontainment Enclosure manufactured by BioBubble. Sole Source Justification: The bioBubble enclosure meets or exceeds stringent biosafety level (BSL-2 and BSL-3) requirements necessary for HIV research. Its unique sealing mechanism and filtration system are specifically designed to prevent contamination and ensure user and environmental safety, capabilities unmatched by alternative suppliers in this product category. This equipment is a key component in our Shared Equipment Inventory to have available to all our Researchers and to provide uninterrupted support in their research. To maintain the highest standard performance, accurate and space-saving scientific equipment is required. This equipment/part are required based on intended experimental design, compatibility with current lab equipment, and the proven ability of the product to produce consistent and reliable data. More specifically, equipment/parts need to be identical to laboratory equipment already in-place. Use of alternate products could negatively impact the manner in which samples are processed and analyzed. Additionally, use of a different product from the one requested would require testing by lab personnel and would introduce unacceptable variables during research trials. This brand name equipment/products are embedded into the several research programs, protocols, and laboratory processes of the lab. To have successful research results, methods and parameters must be consistent. Any changes during the study are unacceptable and may render years of existing data invalid. NIH Safety has approved this model. NO OTHER BRAND IS ACCEPTABLE. The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line shall be referenced, NOI-NIAID-25-2252185) to Kelly Lowe at kelly.lowe@nih.gov by January 02, 2025 10:00 A.m. EST. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

More opportunities from Department Of Health And Human Services → National Institutes Of Health Niaid

Same awarding agency

NAICS: 541715
Federal
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases
Solicitation # HHS-NIH-NIAID-BAA2026-1
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals under Broad Agency Announcement HHS-NIH-NIAID-BAA2026-1 to advance the research and development of medical interventions for infectious diseases. This initiative focuses on three primary research areas: the development of needle-free vaccine candidates through early-phase clinical trials; the creation of safe and effective therapeutic candidates for serious infectious diseases, including those resistant to current antimicrobial therapy; and the innovation of in vitro diagnostic technology platforms capable of rapid, automated detection of a broad panel of priority viral pathogens. The program emphasizes alignment with NIH priorities regarding biosafety, biosecurity, and the use of non-animal testing methods. Proposals must be submitted electronically via the NIAID eCPS website by December 8, 2026, at 3:00 PM Eastern Time. Technical proposals are limited to 75 pages and will be evaluated by a peer review group based on technical merit, with the technical plan and personnel qualifications being of paramount consideration. Awards are not based on a common Statement of Work; instead, offerors must propose their own technical plans, milestones, and cost structures using a base and option period format. The resulting contracts will require an accounting system compliant with generally accepted accounting principles and will involve rigorous government inspection and acceptance based on the successful completion of critical milestones.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

12 days ago

DEADLINE

in about 2 months
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS